Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1996-05-10
1999-10-12
Criares, Theodore J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 3144
Patent
active
059655682
DESCRIPTION:
BRIEF SUMMARY
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to a composition, particularly a pharmaceutical composition, for inhibiting production or secretion of an amyloid .beta. protein. The composition is effective in treating degenerative brain disorders such as senile dementia, Alzheimer's disease, Down's syndrome, etc., amyloid angiopathy, brain disorders caused by amyloid .beta. protein in cerebrovascular diseases, etc.
2. Description of Related Art
Alzheimer's disease is a neurodegenerative disease characterized by senile plaque and neurofibrillar tangles as well as degeneration and loss of neurons. The senile plaques, which are most characteristic of the disease, are deposits composed of amyloid .beta. protein (hereinafter sometimes abbreviated as A.beta.) derived from .beta.-amyloid precursor protein (hereinafter sometimes abbreviated as .beta.APP) as a major component (Biochem. Biophys. Res. Commun., 122, 1131 (1984)), apolipoprotein E (Brain Res., 541, 163 (1991)) and heparan sulfate proteoglycan (Am. J. Pathol., 133, 456 (1988)), etc.
A.beta. of 40 or 42 amino acids exhibits toxicity to neurons (Science, 250, 279 (1990)), and induces neurofibrillar changes (Proc. Natl. Acad. Sci., 90, 7789 (1993)). In patients with familial Alzheimer's disease, mutations on the .beta.APP gene are observed (Lancet, 337, 978 (1991); Nature, 349, 704 (1991); Science, 254, 97 (1991); Nature, 354, 844 (1991)). Cells containing such mutated gene produce and secrete an increased amount of A.beta. (Nature, 360, 672 (1992); Science, 259, 514 (1993); Science, 264, 1336 (1994)).
Patients with Down's syndrome showing cerebral changes pathologically similar to those of Alzheimer's disease (Proc. Natl. Acad. Sci., 82, 4245 (1985)) have trisomy 21 (i.e., three chromosome 21s containing the .beta.APP gene) and promoted expression of the .beta.APP gene and .beta.APP protein in the brain (Science, 235, 880 (1987); N. Eng. J. Med., 320, 1446 (1989)).
Based on these findings, the participation of the abnormal production or secretion of A.beta. in the onset of Alzheimer's disease is considered to be highly important.
It is believed that .beta.APP is metabolized with proteases called .alpha.- and .beta.-secretases through two pathways (Science, 248, 492 (1990); Science, 248, 1122 (1990); Science, 255, 726 (1992); Science, 255, 728 (1992); Nature, 357, 500 (1992)). When .beta.APP is metabolized with a-secretase, .beta.APP is cleaved at position 16 of A.beta., A.beta. is not produced, and the N-terminal fragment of .beta.APP is released out of the cells as secreted .beta.APP, which acts as a neurotrophic factor (Neuron, 10, 243-254 (1993)). On the other hand, when .beta.APP is cleaved with .beta.-secretase, a C-terminal fragment of .beta.APP containing A.beta.is produced. However, it is unclear where the C-terminal fragment or A.beta. is produced in the cells and how A.beta. is secreted out of the cells. In addition, although candidate enzymes for .alpha.- and .beta.-secretases have been reported (J. Biol. Chem., 268, 16699 (1993); Biochemistry, 33, 192 (1994)), they have not identified.
It has been reported that some compounds, phorbol esters (Proc. Natl. Acad. Sci., 89, 3055 (1992)) and M1 muscarinic receptor agonist, carbacol (Science, 258, 302 (1992)) increase the secreted .beta.APP and inhibit A.beta. production or secretion in in vitro various cells. However, these compounds are unsatisfactory in terms of efficacy, safety, etc.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a diagram showing combinations of antibodies used in the EIA system. HRP means horseradish peroxidase.
FIG. 2 shows a standard curve of the EIA system against A.beta. (1-40) and A.beta. (1-42).
FIG. 3 represents graphs showing inhibitory activity of vinpocetine (i.e. the compound of the formula (II) wherein X is hydrogen and R.sup.4 is ethyl) against A.beta. production or secretion in human neuroblastoma IMR-32 cells. Each bar graph indicates the mean value with respect to 4 wells.
FIG. 4 is a graph showing inhibitory activity of vi
REFERENCES:
patent: 4035370 (1977-07-01), Lorincz et al.
patent: 4400514 (1983-08-01), Szantay et al.
patent: 5428035 (1995-06-01), Teleha
Outline of Calan Tablets (in Japanese) and its English translation, Feb. 1987.
C. Nicholson, "Nootropics and metabolically active compounds in Alzheimer's disease", vol. 17, Biochemical Society Transactions, pp. 83-85, Feb. 1989.
Masashi Sasa, "Drugs for Therapy of Dementia", The Japanese Journal of Pharmacology, vol. 49, Official Publication of the Japanese Pharmacological Society, Mar. 25-28, 1989.
R. Bartus et al., "Behavioral and Pharmacological Studies Using Animal Models Aging: Implications for Studying and Treating Dementia of Alzheimer's Type", vol. 15, Banbury Report, pp. 207-218, 1983.
G. Caporaso et al., "Protein Phosphorylation Regulates Secretion of Alzheimer .beta./A4 Aryloid Precursor Protein", Proc. Natl. Acad. Sci., vol. 89, pp. 3055-3059, Apr. 1, 1992.
I. Hindmarch, "Efficacy and Tolerance of Vinpocetine in Ambulant Patients Suffering from Mild to Moderate Organic Psychosyndromes", vol. 6, International Clinical Psychopharmacology, pp. 31-43, 1991.
CA vol. 110, No. 51211 Notvest et al., 1987.
Goto Giichi
Kakihana Mitsuru
Kosaka Takuo
Nagaoka Akinobu
Criares Theodore J.
Takeda Chemical Industries Ltd.
LandOfFree
Composition for inhibiting production or secretion of amyloid .b does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition for inhibiting production or secretion of amyloid .b, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition for inhibiting production or secretion of amyloid .b will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-652747